This work may not be copied, distributed, displayed, published, reproduced, transmitted, modified, posted, sold, licensed, or used for commercial purposes. By downloading this file, you are agreeing to the publisher’s Terms & Conditions.

Original Articles

Olanzapine Augmentation for Treatment-Resistant Obsessive-Compulsive Disorder

Lorrin M. Koran, Alan L. Ringold, and Michael A. Elliott

Published: July 31, 2000

Article Abstract

Background: Adding the atypical neurolepticrisperidone to a serotonin reuptake inhibitor (SRI) has benefitedpatients with treatment-refractory obsessive-compulsive disorder(OCD). Since olanzapine and risperidone have similar serotonergicand dopaminergic receptor binding profiles, we tested thehypothesis that olanzapine augmentation would be beneficial intreatment-unresponsive OCD.

Method: For this 8-week trial, we recruited 10adult OCD patients (DSM-IV criteria) unresponsive to fluoxetine(>= 60 mg/day) for >= 10 weeks, which was continuedthroughout the trial. Other psychotropic medications werediscontinued. Subjects had OCD for >= 1 year, a Yale-BrownObsessive Compulsive Scale (Y-BOCS) score of >= 18, and noorganic, psychotic, or other primary Axis I disorder. Two weeksafter olanzapine, 2.5 mg/day, was added, and in the absence ofresponder status (Y-BOCS score decrease >= 25%) and limitingside effects, we increased the dose to 5 mg/day, and after 2 moreweeks, to 10 mg/day for 4 weeks.

Results: The subjects had failed a mean of 3.3SRI trials (range, 1-5) and had a mean ± SD baseline Y-BOCSscore of 29.0 ± 4.9. Nine patients completed the trial. Thesubjects’ mean ± SD endpoint Y-BOCS score was 24.4 ± 8.0 (a 16%decrease). The 3 responders’ Y-BOCS scores dropped 68%, 30%, and29%, but only 1 patient was rated “much improved.” Hemaintained this improvement during a 6-month follow-up periodtaking olanzapine, 5 mg/day. Improvement in OCD was independentof improvement in mood symptoms. Six patients (60%) experiencedsignificant weight gain.

Conclusion: Olanzapine augmentation may benefittreatment-unresponsive OCD. Double-blind, placebo-controlledtrials are warranted along with trials comparing risperidone andolanzapine augmentation.

Volume: 61

Quick Links: Obsessive-Compulsive and Related Disorders

Continue Reading…

Subscribe to read the entire article

$40.00

Buy this Article as a PDF

Sign-up to stay
up-to-date today!

SUBSCRIBE

Already registered? Sign In

Case Report

Safety and Tolerability of Concomitant Intranasal Esketamine Treatment With Irreversible, Nonselective MAOIs: A Case Series

Three cases suggest that concomitant use of intranasal esketamine with an irreversible, nonselective MAOI is safe in...

Read More...